
Oncolytic Molecules that Kill Cancer with Direct & Abscopal Tumor Effects
Neoadjuvant Immunotherapy with Durable Responses Approaching Registrational Studies
Our Pipeline is Led by Ruxotemitide, Rapidly Approaching Registrational Studies
Asset
Preclinical
Phase I
Phase II
Phase III
Partner
Ruxotemitide (LTX-315)
Neoadjuvant resectable melanoma
Seeking Partners
LTX-401
Deep-seated solid tumors
Seeking Partners
More Pipeline Assets...
Ruxotemitide (LTX-315)
Neoadjuvant resectable melanoma
Seeking Partners
PreIIIIII
LTX-401
Deep-seated solid tumors
Seeking Partners
PreIIIIII
More Pipeline Assets...
News
Latest Press Releases
Nov 17, 2026
Lytix Biopharma ASA: Contemplated private placement and retail offer via Nordnet
Lytix Biopharma ASA: Contemplated private placement and retail offer via Nordnet
Read MoreNov 12, 2026
Lytix Biopharma Q3 2026: Positive NeoLIPA Results Strengthen Basis for Phase III in Melanoma
Lytix Biopharma Q3 2026: Positive NeoLIPA Results Strengthen Basis for Phase III in Melanoma
Read MoreNov 8, 2026
Lytix Biopharma to Present NeoLIPA Phase II Results in Late-Breaking Oral Presentation at ESMO IO 2026
Lytix Biopharma to Present NeoLIPA Phase II Results in Late-Breaking Oral Presentation at ESMO IO 2026
Read More




